Allurion Technologies Inc News - ALUR

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.

“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care.”

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Forward-Looking Statements

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Allurion Technologies Inc (ALUR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ALUR News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion Technologies, Inc. Announces Reverse Stock Split

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Coverage Initiation And Bullish Price Target Sends Micro Cap Flying

ALUR Discussion

Your Recent History